Female Infertility Pipeline Analysis Report 2026

Report Coverage

The Female Infertility Pipeline Analysis Report by Expert Market Research gives comprehensive insights into female infertility therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for female infertility. The female infertility report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The female infertility pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with female infertility treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to female infertility.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Female Infertility Pipeline Outlook

The female infertility pipeline continues to expand with advancements in recombinant hormone therapies, biosimilars, and innovative biologics designed to improve ovarian stimulation and assisted reproductive technology (ART) outcomes. Several candidates targeting follicular development and ovulation induction are progressing through mid- and late-stage clinical trials, reflecting sustained investment in reproductive medicine. In April 2026, Glenmark Pharmaceuticals received U.S. FDA approval for Progesterone Vaginal Inserts, 100 mg, the generic equivalent of Endometrin®, strengthening ART treatment options by supporting embryo implantation and early pregnancy through progesterone supplementation.

Female Infertility Epidemiology

Female infertility remains a major global reproductive health challenge, affecting millions of women of childbearing age. According to the World Health Organization, approximately 17.5% of the global adult population, around 1 in 6 people, experience infertility during their lifetime, highlighting its widespread burden. Female infertility is commonly associated with ovulatory disorders, tubal disease, endometriosis, and age-related decline in ovarian reserve. In the United States, infertility affects approximately 19% of married women aged 15-49 years with no prior births, while increasing maternal age continues to contribute to rising infertility prevalence worldwide.

Female Infertility – Pipeline Therapeutic Assessment

Female Infertility Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III covers a major share of the total female infertility clinical trials. Early Phase I (3.32%), Phase I (13.90%), Phase II (23.44%), Phase III (30.50%), and Phase IV (28.84%) clinical trials. This phase-wise distribution highlights a mature and well-balanced clinical pipeline, reflecting continued advancement in innovative therapies for female infertility.

Female Infertility Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the female infertility pipeline analysis include small molecules, gene therapies, and monoclonal antibodies. The female infertility report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for female infertility. In January 2024, the U.S. FDA approved the Ovaleap® Prefilled Pen for administering Ovaleap® (follitropin alfa), a recombinant follicle-stimulating hormone (rFSH) developed by Theramex. The pen is indicated for women undergoing controlled ovarian stimulation as part of assisted reproductive technologies (ART), including in vitro fertilization (IVF).

Female Infertility Clinical Trials – Key Players

The EMR report for the female infertility pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed female infertility therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in female infertility clinical trials:

• Sclnow Biotechnology Co., Ltd.
• Qilu Pharmaceutical Co., Ltd.
• Ferring Pharmaceuticals
• Hangzhou YuYuan Bioscience Technology Co., Ltd.
• Alphamab Jilin Co., Ltd.
• IVFarma LLC
• LG Life Sciences
• AstraZeneca
• MinaPharm Pharmaceuticals
• ART Fertility Clinics LLC
• Abbott
• Glycotope GmbH

Female Infertility – Emerging Drugs Profile

Key Questions Answered in the Female Infertility Pipeline Insight Report

• Which companies/institutions are leading the female infertility drug development?
• Which company is leading the female infertility pipeline development activities?
• What is the current female infertility commercial assessment?
• What are the opportunities and challenges present in the female infertility pipeline landscape?
• What is the efficacy and safety profile of female infertility pipeline drugs?
• Which company is conducting major trials for female infertility drugs?
• Which companies/institutions are involved in female infertility collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in female infertility?

Reasons To Buy This Report

The Female Infertility Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for female infertility. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into female infertility collaborations, regulatory environments, and potential growth opportunities.

Related Reports

Clinical Trials Market

Infertility Treatment Devices Market

Infertility Drugs Market

Infertility Diagnostics Devices Market